Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
Date:2/14/2012

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2011.

Key Highlights:

  • Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder).  
  • The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA).  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.
  • The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013.
  • Vanda recorded fourth quarter 2011 revenue of $8.4 million including royalties of $1.6 million.  Full year 2011 Fanapt® prescriptions, as reported by IMS, exceeded 120,000, compared to approximately 55,000 for 2010.

  • FULL YEAR 2011 REPORTED RESULTSTotal revenues for the full year 2011 were $31.3 million, compared to $35.7 million for 2010.  Full year 2011 revenues included $4.5 million in Fanapt® royalties received from Novartis, as compared to $3.1 million for the prior year.   Both 2011 and 2010 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt® U.S. and Canadian rights.  2010 full year revenues also included $5.8 million in product sales to Novartis and grant revenue.

    Total operating expenses for 2011 were $42.0 million, compared to $26.9 million for 2010.  The primary driver of the higher expenses in 2011 was the ongoing support of the tasimelteon Non-24-Hour Disorder and MDD clinical studies.

    Vanda recorded a net loss of $9.8 million for 2011, compared to net income of $7.2 million for 2010.  Diluted net loss per share for 2011 was $0.35, compared to diluted net income per share of $0.25 for 2010.

    Vanda's cash, cash equivalents and marketable securities as of December 31, 2011 totaled $167.9 million.

    FOURTH QUARTER 2011 REPORTED RESULTSTotal revenues for the fourth quarter of 2011 were $8.4 million, compared to $7.8 million for 2010. Fourth quarter 2011 revenues included $1.6 million in Fanapt® royalties received from Novartis as compared to royalties of $0.5 million for the fourth quarter of 2010.  

    Total operating expenses for the fourth quarter of 2011 were $14.3 million, compared to $7.0 million for the fourth quarter of 2010.  The primary driver of the higher expenses in the fourth quarter of 2011 was the initiation and ongoing support of the tasimelteon Non-24-Hour Disorder and MDD clinical studies.

    Vanda recorded a net loss of $5.5 million for the fourth quarter of 2011, compared to net income of $2.2 million for the fourth quarter of 2010.  Diluted net loss per share for the fourth quarter of 2011 was $0.20, compared to diluted net income of $0.08 per share for the fourth quarter of 2010.

    Full Year December 31, 2011 Key Financial Figures(1)Twelve Months EndedDecember 31December 31(in thousands, except per share amounts)

    20112010Change ($)Change (%)Total revenues

    $
    31,270$
    35,709$
    (4,439)-12%Research & development  expenses

    28,99612,33816,658135%General & administrative expenses

    11,48610,1471,33913%Non-cash stock-based compensation(2)

    5,5014,98152010%Income (loss) before tax provision

    (10,246)9,269(19,515)-211%Tax provision (benefit)

    (444)2,077(2,521)-121%Net income (loss)

    (9,802)7,192(16,994)-236%Diluted net income (loss) per share

    $
    (0.35)$
    .25$
    (0.60)-240%Fourth Quarter 2011 Key Financial Figures(1)Three Months EndedDecember 31September 30(in thousands, except per share amounts)

    20112011Change ($)Change (%)Total revenues

    $
    8,370$
    7,969$
    4015%Research & development  expenses

    10,5568,1742,38229%General & administrative expenses

    3,3452,71163423%Non-cash stock-based compensation(2)

    1,3181,254645%Loss before tax provision

    (5,809)(3,187)(2,622)-82%Tax benefit

    (286)(113)(173)-153%Net loss

    (5,523)(3,074)(2,449)-80%Diluted net loss per share

    $
    (0.20)$
    (0.11)$
    (0.09)-82%Select Cash Flow Data(1) Twelve Months EndedDecember 31December 31(in thousands)

    20112010Net cash provided by (used in)Operating activities

    (28,410)(10,898)Investing activities

    73,749(155,622)Financing activities

    253,784Net change in cash and cash equivalents

    $
    45,364$
    (162,736)Select Balance Sheet Data(1) December 31September 30December 31(in thousands)

    201120112010Total cash and marketable securities

    $
    7,896$
    80,459$
    98,037(1) Unaudited(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTS   On January 26, 2012, Vanda announced that initial clinical data in the RESET study revealed the potential of tasimelteon to reset the body clock in Non-24-Hour Disorder.  The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 NDA filing with the FDA.   Vanda is in continuing discussions with the FDA to confirm the path and requirements for this regulatory submission.  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.

    The tasimelteon MAGELLAN efficacy study for MDD is ongoing and Vanda expects to report top-line results in the first half of 2013. This Phase IIb/III study in MDD was initiated in September 2011 and is expected to enroll 500 patients across approximately 40 sites.

    Full year 2011 Fanapt® prescriptions, as reported by IMS, exceeded 120,000 compared to approximately 55,000 for 2010.  Vanda has been informed that Novartis is continuing the Phase II development program for the long-acting injectable formulation of Fanapt®.

    The review of Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets in the European Union is ongoing.  The European Medicines Agency (EMA) has provided its standard 120-day list of questions and has granted Vanda a 3-month extension, through mid-May 2012, for Vanda to prepare its response.  After further evaluation of the regulatory and commercial environment, Vanda has no current plans to pursue registration for Fanapt® in Singapore and Australia.  Regulatory filings for market approval of Fanapt® by Vanda's commercial partners are under review in Israel, Mexico and Argentina.  

    CONFERENCE CALLVanda has scheduled a conference call for today, Tuesday, February 14, 2012, at 10:00 AM ET.  During the call, Vanda's management will discuss the fourth quarter and full year 2011 results and other corporate activities.  Investors can call 866-271-0675 (domestic) and 617-213-8892 (international) and use passcode 76685033.  A replay of the call will be available beginning Tuesday, February 14, 2012 at 12:00 PM ET and will be accessible until Tuesday, February 21, 2012, at 5:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 37381299.

    The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days, through March 15, 2012.

    ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products, product candidates or partnered products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products, product candidates or partnered products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

    All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedTwelve Months EndedDecember 31December 31December 31December 31(In thousands, except for per share amounts)

    2011201020112010Revenues:Licensing agreement 

    $

    6,752$

    6,752$

    26,789$

    26,789Royalty revenue 1,6185114,4813,141Product sales---5,290Grant revenue-489-489Total revenues8,3707,75231,27035,709Operating expenses:Cost of sales - product ---2,891Research and development 10,5563,82228,99612,338General and administrative 3,3452,76211,48610,147Intangible asset amortization 3773771,4951,495Total operating expenses14,2786,96141,97726,871Income (loss) from operations (5,908)791(10,707)8,838Other income:Interest income99142461431Total other income99142461431Income (loss) before income tax(5,809)933(10,246)9,269Provision (benefit)Tax provision (benefit)(286)(1,266)(444)2,077Net income (loss)

    $

    (5,523)$

    2,199$

    (9,802)$

    7,192Net income (loss)per share:Basic

    $

    (0.20)$

    0.08$

    (0.35)$

    0.26Diluted

    $

    (0.20)$

    0.08$

    (0.35)$

    0.25Shares used in calculation of net income (loss) per share:Basic

    #

    28,115,17528,038,074#

    28,106,83127,916,388Diluted28,115,17528,892,34728,106,83128,534,617VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(In thousands)

    December 31, 2011December 31, 2010ASSETSCurrent assets:Cash and cash equivalents

    $

    87,923$

    42,559Marketable securities, current60,961155,478Accounts receivable1,618511Prepaid expenses, deposits and other current assets2,9991,843Deferred tax, current -182Total current assets153,501200,573Marketable securities, non-current19,012-Property and equipment, net964937Other assets, non-current84-Intangible asset, net8,0279,522Deferred tax, non-current -1,639Restricted cash1,030430Total assets

    $

    182,618$

    213,101LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    $

    996$

    648Accrued liabilities3,3811,324Accrued income taxes-2,266Deferred rent, current453-Deferred revenue, current26,78926,789Total current liabilities31,61931,027Non-current liabilities:Deferred rent, non-current461490Deferred revenue, non-current117,064143,853Total liabilities149,144175,370Stockholders' equity:Common stock2828Additional paid-in capital296,868291,342Accumulated other comprehensive income212Accumulated deficit(263,443)(253,641)Total stockholders' equity33,47437,731Total liabilities and stockholders' equity

    $

    182,618$

    213,101Company Contact:
    Cristina Murphy
    Senior Communications Manager
    Vanda Pharmaceuticals Inc.
    (240) 599-4500
    cristina.murphy@vandapharma.com


    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
    (Date:5/2/2016)... -- Kalorama Information noted the 5 Most Important Trends ... recent white paper.  The healthcare market research publisher said ... market are among the top drivers of market growth. ... EMR 2016: The Market for Electronic Medical Records ... the EMR industry, and the report is consulted by ...
    (Date:5/2/2016)... 2016 The global  ultrasound ... billion by 2024, according to a new report ... of the sonography market include expanding applications of ... for periodic ultrasound screenings of the breast for ... ) High Intensity Focused Ultrasound ...
    Breaking Medicine Technology:
    (Date:5/4/2016)... Carlsbad, CA (PRWEB) , ... May 04, 2016 , ... ... has recently partnered with local company MitoXcell in preparation of the launch of her ... day jump start plan is a nutritional guide designed to jump start a new ...
    (Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
    (Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its ... seminar on stem cell injections. The seminar is scheduled for Wednesday, May 18, from ... Suite 110, Ventura, CA. There are only 10 seats available. , “The purpose ...
    (Date:5/4/2016)... ... May 04, 2016 , ... ... and support for knees, ankles, and elbows. Engineered with athletes in mind, ... flat-bed manufacturing (opposed to ineffective circular knitting, common in the industry) produces ...
    (Date:5/4/2016)... , ... May 03, ... manufacturer of innovative infant and child products, today revealed the non-toxic ... ability to help babies deal with teething pain is just part ... no toxic gels, and are BPA-, PVC-, and phthalate-free. , ...
    Breaking Medicine News(10 mins):